Glucose


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Glucose tolerance test 75 g as a single dose. Measure serum glucose at intervals. Hypoglycaemia 4-20 g as a single dose, repeat as needed. IV Carbohydrate depletion As >5% soln: Dosage is based on individual patient requirements. Fluid depletion As 5% soln: Dosage is based on individual patient requirements. Hypoglycaemia 10-25 g as a single dose, repeat if necessary.
Dosage Details
Intravenous
Hypoglycaemia
Adult: 10-25 g (40-100 mL of 25% soln or 20-50 mL of 50% soln) as a single dose via central vein, repeat if necessary in severe cases.
Child: 0.5-1 g/kg/dose. Max: 25 g/dose.

Intravenous
Fluid depletion
Adult: As 5% soln given via peripheral vein. Dosage is based on individual patient requirements.

Intravenous
Carbohydrate depletion
Adult: As >5% soln given via peripheral vein. Dosage is based on individual patient requirements.

Oral
Hypoglycaemia
Adult: 4-20 g as a single dose, repeat as necessary.
Child: 15-20 g as a single dose, repeat after 15 min if necessary.

Oral
Oral glucose tolerance test
Adult: 75 g as a single dose.
Contraindications
Hypersensitivity to glucose, corn or corn products. Patient w/ severe dehydration, glucose-galactose malabsorption syndrome, ischaemic stroke. Admin of hypertonic soln in patients (esp if dehydrated) w/ intracranial or intraspinal haemorrhage, diabetic coma, delirium tremens.
Special Precautions
Patient w/ DM, chronic uraemia, thiamine deficiency, severe traumatic brain injury, water and electrolyte imbalance, haemodilution, sepsis, and severe malnutrition. Avoid abrupt withdrawal. Renal failure. Childn (esp low birth wt infants). Pregnancy and lactation.
Adverse Reactions
Significant: Electrolyte imbalance (e.g. hypokalaemia), dehydration, severe hypersensitivity reactions (e.g. anaphylaxis).
CV: Localised phlebitis, venous irritation and thrombosis, thrombophlebitis.
Resp: Pulmonary vascular precipitates and oedema.
Hepatic: Hepatic failure, cirrhosis, cholestasis, steatosis, increased bilirubin and hepatic enzyme, cholecystitis, cholelithiasis.
Genitourinary: Diuresis.
Endocrine: Glycosuria, hyperosmolar syndrome, hypervolaemia.
Dermatologic: Rash.
Others: Catheter infection, sepsis, chills, fever, infusion site reactions (e.g. erythema and pain).
Potentially Fatal: Severe hyperglycaemia and hyponatraemia.
IV/Parenteral: C
MonitoringParameters
Monitor serum and urine glucose, serum electrolytes, intake and output (I & O), caloric intake.
Overdosage
Symptoms: Hyperglycaemia, water intoxication or oedema, and glycosuria. Management: Symptomatic and supportive treatment.
Action
Description: Glucose, the natural sugar occurring in blood, is the primary source of energy in cellular metabolism. It is readily converted to fat which provides a rich store of energy in concentrated form, and it also promotes glycogen deposition in the liver.
Onset: 10 min (oral).
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Bioavailability: 100% (IV). Time to peak plasma concentration: Approx 40 min (oral).
Metabolism: Metabolised in the liver by pyruvic or lactic acid to CO2 and water w/ energy release.
Storage
Store below 25°C. Protect from extreme heat. Do not freeze.
ATC Classification
V06DC01 - glucose ; Belongs to the class of carbohydrates used as general nutrients.
V04CA02 - glucose ; Belongs to the class of diagnostic agents used to test for diabetes.
References
Anon. Dextrose. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 25/05/2017.

Buckingham R (ed). Glucose. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 25/05/2017.

Joint Formulary Committee. Glucose. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 25/05/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Dextrose. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 25/05/2017.

Disclaimer: This information is independently developed by MIMS based on Glucose from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • A.N.B. Glucose Injection 25%/50%
  • D5 Albert David/D10 Albert David
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in